Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 163,038	$ 293,503
Marketable securities	376,087	0
Prepaid expenses	6,861	5,994
Other current assets	1,286	5,206
Total current assets	547,272	304,703
Property and equipment, net	244	245
Intangible assets	102,500	102,500
Goodwill	6,234	6,234
Other assets	3,380	3,931
Total assets	659,630	417,613
Current liabilities:
Accounts payable	4,110	3,356
Accrued clinical trial expenses	10,674	8,657
Accrued compensation	5,039	6,616
Other accrued liabilities	2,413	1,842
Current portion of contingent consideration	32,500	0
Common stock warrant liabilities	607	512
Total current liabilities	55,343	20,983
Contingent consideration, net of current portion	47,600	76,900
Deferred income taxes	17,425	17,425
Other long-term liabilities	482	784
Total liabilities	120,850	116,092
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.001 par value; 50,000 shares authorized; 35,827 and 34,808 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	42	35
Additional paid-in capital	1,212,305	873,526
Accumulated deficit	(673,521)	(572,040)
Accumulated other comprehensive loss	(46)	0
Total stockholders’ equity	538,780	301,521
Total liabilities and stockholders’ equity	$ 659,630	$ 417,613